Membranoproliferative glomerulonephritis (MPGN) is not a common disease. There are few studies in China, especially for treatment and prognosis. We reviewed the clinical and pathological features of 51 patients who were diagnosed to have primary idiopathic MPGN. Most patients presented with hematuria, proteinuria, or nephrotic syndrome. Almost half of the patients had hypertension and impaired renal function at presentation. Patients with type I MPGN, renal vascular disease, or tubulointerstitial abnormality in the renal biopsy specimens frequently presented with hypertension and renal impairment. Patients with type III MPGN often presented with nephrotic syndrome. In general, children had less severe disease than adults did. Patients were followed for an average of 9.5 years (ranged from 9 months to 26 years). Five patients developed end-stage renal failure during follow-up (3 to 25 years after initial presentation), four patients died during the follow-up period. There was a beneficial effect of steroid therapy, with or without systemic anticoagulation (urokinase, heparin, followed by warfarin and dipyridamole). Immunosuppressive treatment commonly reduced proteinuria and improved renal function. In summary, MPGN is an aggressive disease with poor long-term prognosis. Steroid therapy, with or without anticoagulants, may have a beneficial effect.
INTRODUCTION
decreasing (1, 2) . The incidence of MPGN varies between 10.6% and 13.8% of all glomerulonephritis (GN) in China (3, 4) . The pathogenesis of MPGN is unknown (5) . Patients of MPGN have a poor prognosis, and no treatment has been proved effective. There are very few prednisone together with urokinase 20000 unit/day, and heparin 50 mg/day to 70 mg/day subcutaneously for 4 weeks, and then dipyridamole 75 mg/day orally and warfarin 2.5 mg/day for at least 4 weeks. International normalized ratio (INR) was monitored to keep below 3.0. Five patients received prednisone, anticoagulant, and cyclophosphamide 100 mg daily intravenously and indomethacin 12.5 mg thrice daily orally for 1 month. The total dosage of cyclophosphamide give ranged from 2 g to 4 g.
Statistical analysis
All data were expressed as mean +standard error of mean (SE) unless otherwise specified. Characteristics between groups were performed by Chi-square test, Student's ttest, and one-way analysis of variance (ANOVA). P values less than 0.05 was considered significant. All probabilities were two-tailed.
RESULTS
Of the 51 patients, 29 were males, and 22 females. Their age at presentation was 28.8 ±14.5 years. In all cases, light microscopy revealed a diffuse proliferative GN with thickening of the glomerular capillary walls, increased in mesangial cells and matrix, and a lobulated appearance of the glomerulus. Immunofluorescence studies were available for 45 biopsies. The result was shown in table 1. Twenty-one specimens were examined by electron microscopy. In 14 specimens, subendothelial 
PATIENTS AND METHODS
We identified 51 patients with renal biopsy between 1979 and 1995 that confirmed a diagnosis of idiopathic MPGN. Secondary causes, such as systemic lupus erythematosus, were excluded. All renal biopsy tissues were examined by light microscopy, 45 were examined by immunofluorescence, including IgG, IgA, IgM, C3, HBsAg, and 21 specimens were examined by electron microscopy. Pathologic criteria of glomerular disease by WHO classification in 1982 were used (6) . Tubulointerstitial abnormality were classified semiquantitatively into either mild or serious: mild denoted few tubules atrophy or hypertrophy, and less then 25% focal interstitial infiltration and fibrosis; serious denoted significant tubules atrophy or hypertrophy, or more than 25% interstitial infiltration and fibrosis. Vessel lesions including arteriole intimal fibrosis or arteriole hyaline degeneration were also scored.
Eight patients received no immunosuppressive therapy or anticoagulant. Thirteen patients were treated with prednisone alone, with a starting dosage of 30 mg/day to 60 mg/day for at least 8 weeks, 25 patients received and mesangial deposits could be seen, confirming type I MPGN. In seven specimens, there were subendothelial, subepithelial and mesangial deposits, confirming type III MPGN. There has no case of type II MPGN identified in our series. Clinical features at presentation were summarized in table 2.
The clinical features of type I MPGN and type III MPGN were compared and summarized in table 3. We found that blood pressure in cases of type I was slightly higher than that in type III MPGN. Initial creatinine clearance was lower in type I than that in type III, and proteinuria was more serious in type III than that in type I. Nephrotic syndrome was found to be more in type III patients than that in type I patients (85.7% vs 21.4 % cases, p < 0.05).
Clinical features of adults and children (age less than 15 years) were compared and shown in table 4. Adults frequently presented with hypertension and renal impairment, while children frequently presented with macroscopic hematuria. The relationship of clinical features with renal vascular abnormalities and tubulointerstitial abnormalities were summarized in table  5 and table 6 respectively. Patients that presented with hypertension and renal function impairment generally had more severe renal vascular and tubulointerstitial abnormalities.
Twenty-five patients (49.0%) had low serum C3 level and 11 patients (21.6%) had low serum CH50 concentration at diagnosis. We found that serum complement level fluctuate with time, and returned to normal in six patients. We found no relationship between complement levels and clinical presentation, disease severity and response to treatment (details not shown).
In addition, immunofluorescence appearance did not correlate with clinical features and disease severity. Patients with hypocomplementemia tended to have positive C3 staining in immunofluorescence study (details not shown). The short-and long-term effects of treatment modality are shown in table 7 and table 8 respectively. Thirtyeight of our patients were treated for 8 weeks to 26 years. There were no significant differences in baseline clinical features and histology between controlled and treatment group (details not shown). In general, regimens including prednisone, with or without anticoagulants, were useful in reducing proteinuria and improving renal function. There were no major side effects noted with immunosuppressive and anticoagulant therapy.
Our patients were followed for an average of 9.5 ±13.1 
DISCUSSION
MPGN is characterized by diffuse mesangial cells and matrix proliferation with glomerular capillary wall thickening. There are three main morphologic categories.
In the present series, 21 specimens had electron microscopy classification: 14 were type I MPGN, and seven were type III MPGN. We did not find any case of type II MPGN. Clinical features were variable. One-third of the patients had preceding upper respiratory tract infection. Clinical features were similar to the report series (1, (7) (8) (9) . Almost half of our patients had anemia at presentation that was not explained by the degree of renal failure. This anemia was possibly related to the presence of activated complement on the surface of the red cells (1, 2) . Almost one half of our patients had hypocomplementemia, similar to a previous report (2) . Since many patients with hypocomplementemia had C3 positive in immunofluorescence, it was possible that C3 deposition in glomerulus caused hypocomplementemia.
We found that patients of type I MPGN frequently presented with hypertension and renal function impairment, while type III MPGN often presented with nephrotic syndrome. We found cases of type I MPGN commonly had crescents, glomerulosclerosis, and serious tubulointerstitial abnormality, while type III MPGN often had prominent basement membrane changes and subepithelial electron-dense deposits. Our observations were similar to the report of Chen et al (10) .
Similar to the report of Cameron (11) , children more frequently presented with macroscopic hematuria. In general, renal function deteriorates less rapidly in children than that in adults. However, the outcome of children is also poor 10 years after initial diagnosis. Interestingly, in our study, we found that the histopathology changes of adult MPGN were more serious than that in children. This is contrary to the observation by Cameron (11) .
In our series, renal vascular lesions can be seen in 16 cases. The changes included arteriole intimal fibrosis and hyaline degeneration of arteriole. Hematuria, hypertension, renal function impairment and anemia were more frequent in patients with renal vascular lesions. This observation is similar to that by Kincaid-Smith (12) . Tubulointerstitial lesions were also common in our series. We found that tubulointerstitial abnormalities correlated closely with the rate of renal function deterioration and prognosis. Our observations agreed with many other reports (12, 14, 15) .
In our series, nine patients (17.6%) developed end-stage renal failure after a median follow-up of 9 years. Nephrotic syndrome, hypertension, impaired renal func tion, and presence of crescents, sclerosis, and tubulointerstitial abnormalities in biopsy specimens were poor prognostic factors. These observations were similar to most reports (11, 16, 17) .
In our study, 13 patients were treated with prednisone alone, and 25 had prednisone with anticoagulant. Our data suggested that immunosuppressive and anticoagulant therapy could reduce proteinuria and slow the rate of decline of renal function. However, the effect was apparently not long-lasting. In our series, most patients discontinued with the treatment at their own will after initial clinical remission. Only four patients received steroid for over 6 months. One of them developed end stage renal disease 16 years after biopsy. The other three had normal renal function up to 26 years after biopsy. Cameron suggested that steroid should be maintained at a low-dose to achieve long-term benefit (18) .
In summary, MPGN is an aggressive disease with poor long-term prognosis. Steroid therapy, with or without anticoagulants, may have a beneficial effect. However, the optimal duration of therapy remains to be determined.
